Browsing by Author "Aksu, G"

Now showing 1 - 4 of 4
  • No Thumbnail Available
    Item
    Screening Di George Syndrome with A Single Tube of Blood in Cases with Congenital Cardiopathies
    Aksu, G; Karaca, NE; Koroglu, OA; Karaca, E; Kanik, ET; Levent, E; Ozkinay, F
  • No Thumbnail Available
    Item
    Early Immunomodulatory Effects of Different Natural Surfactant Preparations in Preterms With Respiratory Distress
    Yalaz, M; Tanriverdi, S; Uygur, Ö; Köroglu, ÖA; Azarsiz, E; Aksu, G; Kültürsay, N
    BackgroundRespiratory distress syndrome (RDS) is the most common respiratory disease in premature infants. Exogenous natural surfactant preparations are used in the treatment of RDS. In recent years, it has become increasingly evident that surfactant plays an immunoregulatory role. ObjectivesThe aim of this study was to evaluate cytokine and chemokine response following three different regimens of natural surfactant treatment in preterm newborns with RDS. MethodsPremature newborns below 32 weeks of gestation who were intubated for RDS and given early surfactant rescue therapy were included in the study. Newborns were randomly divided into three groups and Beractant 100 mg/kg (B-100), Poractant alfa 100 mg/kg (P alpha-100) and Poractant alfa 200 mg/kg (P alpha-200) were administered intratracheally. Blood samples and transtracheal aspirates (TA) were collected just before and 4-6 h after the surfactant treatment. Total eosinophil count, inducible T Cell alpha chemoattractant (ITaC), macrophage inflammatory protein 3 beta (MIP3b), interleukins (IL) 5, 8, 9, 10, 13, immunoglobulin E (IgE), interferon gamma (IFN-gamma), eotaxin and tumor necrosis factor beta-1 (TGF-beta 1) were measured from blood and tracheal aspirate samples. ResultsA total of 45 infants, 15 in each group, were included in the study. Mean gestational age, birth weight, antenatal, demographic and clinical characteristics of the study groups were similar. IFN gamma concentration and eosinophil counts in TA decreased after surfactant replacement in all groups, especially in the infants treated with P alpha-100 and P alpha-200. Eotaxin, TGF beta and IL-8 concentrations in TA increased significantly in the infants treated with P alpha-100 and P alpha-200. IL-9 levels in TA decreased in the B-100 group but increased in the P alpha-100 and P alpha-200 groups. Blood levels of cytokines and chemokines showed significantly decreased levels of ITaC and MIP3b only in the B-100 group, but no significant change was observed in the P alpha-100 and P alpha-200 groups. ConclusionIn our study, the different immunomodulatory effects of natural surfactant preparations on newborn lung is proven. We found that Poractant alpha, one of the natural surfactant preparations, shifted the lung immune system toward TH2.
  • No Thumbnail Available
    Item
    Patterns of care for lung cancer in radiation oncology departments of Turkey
    Demiral, A; Alicikus, ZA; Ugur, V; Karadogan, I; Yoney, A; Andrieu, MN; Yalman, D; Pak, Y; Aksu, G; Ozyigit, G; Ozkan, L; Kilciksiz, S; Koca, S; Caloglu, M; Yavuz, A; Caglar, H; Beyzad-eoglu, M; Igdem, S; Serin, M; Kaplan, B; Koc, M; Korkmaz, E; Celik, OK; Kinay, M
  • No Thumbnail Available
    Item
    PATTERNS OF CARE FOR LUNG CANCER IN RADIATION ONCOLOGY DEPARTMENTS OF TURKEY
    Demiral, AN; Alicikus, ZA; Ugur, VI; Karadogan, I; Yöney, A; Andrieu, MN; Yalman, D; Pak, Y; Aksu, G; Özyigit, G; Özkan, L; Kilçiksiz, S; Koca, S; Çaloglu, M; Yavuz, AA; Çaglar, HB; Beyzadeoglu, M; Igdem, S; Serin, M; Kaplan, B; Koç, M; Korkmaz, E; Karakoyun-Çelik, Ö; Dinçer, S; Kinay, M
    Purpose: To determine the patterns of care for lung cancer in Turkish radiation oncology centers. Methods and Materials: Questionnaire forms from 21 of 24 (87.5%) centers that responded were evaluated. Results: The most frequent histology was non-small cell lung cancer (NSCLC) (81%). The most common postoperative radiotherapy (RT) indications were close/(+) surgical margins (95%) and presence of pN2 disease (91%). The most common indications for postoperative chemotherapy (CHT) were >= IB disease (19%) and the presence of pN2 disease (19%). In Stage IIIA potentially resectable NSCLC, the most frequent treatment approach was neoadjuvant concomitant chemoradiotherapy (CHRT) (57%). In Stage IIIA unresectable and Stage IIIB disease, the most frequent approach was definitive concomitant CHRT (91%). In limited SCLC, the most common treatment approach was concomitant CHRT with cisplatin+etoposide for cycles 1-3, completion of CHT to cycles 4-6, and finally prophylactic cranial irradiation in patients with complete response (71%). Six cycles of cisplatin + etoposide CHT and palliative thoracic RT, when required, was the most commonly used treatment (81%) in extensive SCLC. Sixty-two percent of centers did not have endobronchial brachytherapy (EBB) facilities. Conclusion: There is great variation in diagnostic testing, treatment strategies, indications for postoperative RT and CHT, RT features, and EBB availability for LC cases. To establish standards, national guidelines should be prepared using a multidisciplinary approach. (c) 2008 Elsevier Inc.